1. World Health Organization (WHO). The importance of pharmacovigilance: safety monitoring of medicinal products. Genève: WHO; 2002. https://apps.who.int/medicinedocs/pdf/s4893e/s4893e.pdf. Accessed 28 Sep 2020.
2. Heads of Medicines Agency, European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module XVI, Risk Minimisation measures: selection of tools and effectiveness indicators (Rev 2). 28 Mar 2017. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-xvi-risk-minimisation-measures-selection-tools_en-3.pdf. Accessed 28 Sep 2020.
3. Heads of Medicines Agency, European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module V, Risk management systems (Rev. 2). 28 March 2017. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-rev-2_en.pdf. Accessed 29 Sep 2020.
4. European Parliament and the Council of the European Union. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. 2004 Official Journal of the European Union L 136/34 https://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/dir_2004_27/dir_2004_27_en.pdf. Accessed 29 Sep 2020.
5. European Commission. Guideline on the readability of the labelling and package leaflet of medicinal products for human use. Revision 1. 2009. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-2/c/2009_01_12_readability_guideline_final_en.pdf. Accessed 20 Jan 2020.